Alizyme
Alizyme is a drug development company dedicated to providing treatments for diseases with high unmet medical needs, including irritable bowel syndrome, inflammatory bowel disease, obesity, diabetes, and mucositis. The company focuses on developing new products to meet patient needs and owns the intellectual property rights to several drug candidates in clinical trials. It emphasizes outsourcing and collaborates with service providers to focus investment on development programs.
Industries
Nr. of Employees
small (1-50)
Products
Development-stage colonic-targeted anti-inflammatory candidate
A clinical-stage therapeutic candidate intended for local treatment of inflammatory bowel disease using a colonic-targeted delivery approach.
Clinical-stage therapeutic candidate for irritable bowel syndrome
A development-stage candidate targeting symptoms of irritable bowel syndrome.
Clinical-stage metabolic disease candidate (obesity and diabetes)
A development-stage therapeutic candidate aimed at obesity and related metabolic disorders including diabetes.
Clinical-stage therapeutic candidate for mucositis
A development-stage candidate intended to prevent or treat mucositis associated with cancer therapy.
Colonic-targeted drug delivery platform (development and licensing)
A technology platform for targeted delivery of therapeutics to the colon, available for licensing to developers of colon-targeted therapies.
Development-stage colonic-targeted anti-inflammatory candidate
A clinical-stage therapeutic candidate intended for local treatment of inflammatory bowel disease using a colonic-targeted delivery approach.
Clinical-stage therapeutic candidate for irritable bowel syndrome
A development-stage candidate targeting symptoms of irritable bowel syndrome.
Clinical-stage metabolic disease candidate (obesity and diabetes)
A development-stage therapeutic candidate aimed at obesity and related metabolic disorders including diabetes.
Clinical-stage therapeutic candidate for mucositis
A development-stage candidate intended to prevent or treat mucositis associated with cancer therapy.
Colonic-targeted drug delivery platform (development and licensing)
A technology platform for targeted delivery of therapeutics to the colon, available for licensing to developers of colon-targeted therapies.
Services
Licensing of clinical-stage drug candidates and platform technologies to pharmaceutical partners for further development and commercialization.
Coordination and oversight of external collaborators and contract research organisations to execute laboratory, preclinical and clinical development activities.
Program-level planning and management of clinical development activities to generate efficacy data supporting regulatory or commercial decisions.
Editorial production of comparative reviews, ingredient analyses, and buyer guidance for dietary supplements and consumer health products, with optional referral links to vendors.
Licensing of clinical-stage drug candidates and platform technologies to pharmaceutical partners for further development and commercialization.
Coordination and oversight of external collaborators and contract research organisations to execute laboratory, preclinical and clinical development activities.
Program-level planning and management of clinical development activities to generate efficacy data supporting regulatory or commercial decisions.
Editorial production of comparative reviews, ingredient analyses, and buyer guidance for dietary supplements and consumer health products, with optional referral links to vendors.
Expertise Areas
- Clinical development management
- Regulatory dossier preparation
- Colonic-targeted drug delivery
- Gastrointestinal therapeutics
Key Technologies
- Colonic-targeted delivery systems
- Clinical trial design and execution
- Translational research methodologies
- Regulatory submission package preparation